Steven Lentz

List of Publications by Year in Descending Order

196 papers	9,328 citations	55 h-index	91 g-index
202 ext. papers	10,185 ext. citations	7.6 avg, IF	6.07 L-index

#	Paper	IF	Citations
196	Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study.. *Journal of Thrombosis and Haemostasis*, **2022**,	15.4	2
195	Turoctocog alfa pegol (N8-GP) in severe hemophilia A: Long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study.. *Research and Practice in Thrombosis and Haemostasis*, **2022**, 6, e12674	5.1	
194	Myeloid Cell PKM2 Deletion Enhances Efferocytosis and Reduces Atherosclerosis.. *Circulation Research*, **2022**, 101161CIRCRESAHA121320704	15.7	1
193	Smooth Muscle Cell-Specific PKM2 (Pyruvate Kinase Muscle 2) Promotes Smooth Muscle Cell Phenotypic Switching and Neointimal Hyperplasia. *Arteriosclerosis, Thrombosis, and Vascular Biology* , **2021**, 41, 1724-1737	9.4	9
192	Thrombotic potential during pediatric acute lymphoblastic leukemia induction: Role of cell-free DNA. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, e12557	5.1	1
191	Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2225-2234	15.4	37
190	The metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis. *Blood*, **2021**, 137, 1658-1668	2.2	5
189	Cooling down VITT with IVIG. *Blood*, **2021**, 138, 921-922	2.2	3
188	Targeting Myeloid-Specific Integrin 91 Improves Short- and Long-Term Stroke Outcomes in Murine Models With Preexisting Comorbidities by Limiting Thrombosis and Inflammation. *Circulation Research*, **2020**, 126, 1779-1794	15.7	21
187	Pilot trial of semi-automated medical note writing using lexeme hypotheses. *International Journal of Medical Informatics*, **2020**, 136, 104095	5.3	
186	Memantine Protects From Exacerbation of Ischemic Stroke and Blood Brain Barrier Disruption in Mild But Not Severe Hyperhomocysteinemia. *Journal of the American Heart Association*, **2020**, 9, e013368	6	11
185	Smooth muscle cell-specific fibronectin-EDA mediates phenotypic switching and neointimal hyperplasia. *Journal of Clinical Investigation*, **2020**, 130, 295-314	15.9	24
184	Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1). *Journal of Thrombosis and Haemostasis*, **2020**, 18, 341-351	15.4	8
183	Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials. *Haemophilia*, **2020**, 26, 450-458	3.3	6
182	Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study. *Journal of Thrombosis and Haemostasis*, **2019** , 17, 1144-1152	15.4	21
181	Is Homoarginine a Protective Cardiovascular Risk Factor?. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 869-875	9.4	20
180	Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). *Haemophilia*, **2019**, 25, 373-381	3.3	25

179	Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A. *Research and Practice in Thrombosis and Haemostasis*, **2019**, 3, 542-554	5.1	9
178	Nox2 NADPH oxidase is dispensable for platelet activation or arterial thrombosis in mice. *Blood Advances*, **2019**, 3, 1272-1284	7.8	20
177	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. *Blood*, **2018**, 131, 2151-2160	2.2	38
176	Fibronectin Containing Extra Domain A Induces Plaque Destabilization in the Innominate Artery of Aged Apolipoprotein E-Deficient Mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 500-508	9.4	13
175	The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 352-363	15.4	13
174	Helicopter "Drip and Ship" Flights Do Not Alter the Pharmacological Integrity of rtPA. *Journal of Stroke and Cerebrovascular Diseases*, **2018**, 27, 2720-2724	2.8	8
173	Haemophilia clinical care and research needs: Assessing priorities. *Haemophilia*, **2018**, 24, e270-e273	3.3	
172	Targeting platelet EPCR for better therapeutic factor VIIa activity. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 1814-1816	15.4	
171	Letter by Sonkar et al Regarding Article, "Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase". *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, e25	9.4	1
170	Fibrin films: overlooked hemostatic barriers against microbial infiltration. *Journal of Clinical Investigation*, **2018**, 128, 3243-3245	15.9	3
169	Prospective Diagnosis of VWD in a Large Cohort of Patients with Bleeding Symptoms through the Zimmerman Program. *Blood*, **2018**, 132, 979-979	2.2	1
168	Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism. *Blood*, **2018**, 132, 2506-2506	2.2	2
167	Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. *Haemophilia*, **2018**, 24, e391-e394	3.3	12
166	Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm trials. *Haemophilia*, **2018**, 24, 911-920	3.3	9
165	ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 1332-1338	9.4	14
164	Clinical and laboratory phenotype variability in type 2M von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 1559-1566	15.4	10
163	Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1. *Cell Stem Cell*, **2017**, 21, 359-373.e5	18	32
162	Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 1971-1976	15.4	10

161	The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial. *Blood Coagulation and Fibrinolysis*, **2017**, 28, 224-229	1	1
160	On PAR with aPC to target inflammasomes. *Blood*, **2017**, 130, 2579-2581	2.2	0
159	Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. *Thrombosis and Haemostasis*, **2017**, 117, 252-261	7	74
158	Whole-exome sequencing in evaluation of patients with venous thromboembolism. *Blood Advances*, **2017**, 1, 1224-1237	7.8	40
157	Deficiency of superoxide dismutase promotes cerebral vascular hypertrophy and vascular dysfunction in hyperhomocysteinemia. *PLoS ONE*, **2017**, 12, e0175732	3.7	16
156	D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment. *Thrombosis Research*, **2016**, 146, 119-125	8.2	11
155	Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. *Blood*, **2016**, 127, 2481-8	2.2	76
154	Hypomorphic mutations in TRNT1 cause retinitis pigmentosa with erythrocytic microcytosis. *Human Molecular Genetics*, **2016**, 25, 44-56	5.6	51
153	Protein methionine oxidation augments reperfusion injury in acute ischemic stroke. *JCI Insight*, **2016**, 1,	9.9	16
152	the NADPH Oxidase Catalytic Subunit Nox2 Displays Differential Roles in Arterial Vs. Venous Thrombosis. *Blood*, **2016**, 128, 4907-4907	2.2	
151	Dok-1 negatively regulates platelet integrin IIbβ3 outside-in signalling and inhibits thrombosis in mice. *Thrombosis and Haemostasis*, **2016**, 115, 969-78	7	5
150	Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. *Thrombosis and Haemostasis*, **2016**, 116, 42-9	7	19
149	Genetic testing to guide warfarin dosing: Impact of direct oral anticoagulants. *Clinical Pharmacology and Therapeutics*, **2016**, 100, 128-30	6.1	3
148	Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. *Haemophilia*, **2016**, 22, e445-9	3.3	6
147	Thrombosis in the setting of obesity or inflammatory bowel disease. *Blood*, **2016**, 128, 2388-2394	2.2	38
146	Thrombosis in the setting of obesity or inflammatory bowel disease. *Hematology American Society of Hematology Education Program*, **2016**, 2016, 180-187	3.1	13
145	Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm®4). *Thrombosis Research*, **2016**, 141, 69-76	8.2	46
144	Endothelial PPAR-δ protects against vascular thrombosis by downregulating P-selectin expression. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 838-44	9.4	26

143	Case report: paroxysmal cold hemoglobinuria presenting during pregnancy. *BMC Hematology*, **2015**, 15, 3	2.5	3
142	Homocysteine **2015**, 53-62		
141	Fibronectin Splicing Variants Containing Extra Domain A Promote Atherosclerosis in Mice Through Toll-Like Receptor 4. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 2391-400	9.4	42
140	Deficiency of superoxide dismutase impairs protein C activation and enhances susceptibility to experimental thrombosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 1798-804	9.4	12
139	Genetic Ablation of Extra Domain A of Fibronectin in Hypercholesterolemic Mice Improves Stroke Outcome by Reducing Thrombo-Inflammation. *Circulation*, **2015**, 132, 2237-47	16.7	31
138	Deletion of Methionine Sulfoxide Reductase A Does Not Affect Atherothrombosis but Promotes Neointimal Hyperplasia and Extracellular Signal-Regulated Kinase 1/2 Signaling. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 2594-604	9.4	7
137	D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. *Annals of Internal Medicine*, **2015**, 162, 27-34	8	96
136	Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian® clinical trials. *Haemophilia*, **2015**, 21, 34-40	3.3	29
135	Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®)) in previously treated patients with severe haemophilia A: interim results of the guardian(®)2 extension trial. *Haemophilia*, **2015**, 21, e436-9	3.3	10
134	Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet Toll-like receptor 4. *Blood*, **2015**, 125, 3164-72	2.2	46
133	Regulation of thrombosis and vascular function by protein methionine oxidation. *Blood*, **2015**, 125, 3851-9	2.2	35
132	Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 1989-98	15.4	40
131	Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. *Haemophilia*, **2014**, 20, 527-34	3.3	37
130	AGXT2: a promiscuous aminotransferase. *Trends in Pharmacological Sciences*, **2014**, 35, 575-82	13.2	46
129	Turoctocog alfa and drug development for hemophilia A. *Expert Opinion on Orphan Drugs*, **2014**, 2, 419-431	2.1	2
128	Protective vascular and cardiac effects of inducible nitric oxide synthase in mice with hyperhomocysteinemia. *PLoS ONE*, **2014**, 9, e107734	3.7	13
127	Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 1244-53	15.4	55
126	A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project. *Journal of Blood Medicine*, **2014**, 5, 1-3	2.3	5

125	Factor VIII Dosing and Preventive Efficacy in Obese Patients with Hemophilia (BMI ≥30 kg/m2) – a Post-Hoc Sub-Analysis of the guardian™ Trials. *Blood*, **2014**, 124, 1503-1503	2.2	4
124	Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial. *Blood*, **2014**, 124, 2846-2846	2.2	1
123	Results from a large multinational clinical trial (guardian™) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. *Haemophilia*, **2013**, 19, 691-7	3.3	70
122	Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2013**, 304, R690-701	3.2	31
121	Mechanisms of thrombosis in obesity. *Current Opinion in Hematology*, **2013**, 20, 437-44	3.3	152
120	Trends in clinical laboratory homocysteine testing from 1997 to 2010: the impact of evidence on clinical practice at a single institution. *Clinical Chemistry and Laboratory Medicine*, **2013**, 51, 671-5	5.9	
119	Hydrogen peroxide promotes aging-related platelet hyperactivation and thrombosis. *Circulation*, **2013**, 127, 1308-16	16.7	113
118	Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 1300-9	15.4	43
117	Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 670-8	15.4	124
116	Dissecting The Effects Of Isoprenoid Pathway Inhibition On Hemostasis and Thrombosis: Differential Effects Of Atorvastatin and Digeranyl Bisphosphonate In Hypercholesterolemic Mice. *Blood*, **2013**, 122, 2378-2378	2.2	
115	Critical von Willebrand factor A1 domain residues influence type VI collagen binding. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 1417-24	15.4	49
114	ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. *Blood*, **2012**, 119, 2385-91	2.2	78
113	ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 1665-71	15.4	64
112	Paradoxical absence of a prothrombotic phenotype in a mouse model of severe hyperhomocysteinemia. *Blood*, **2012**, 119, 3176-83	2.2	29
111	Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 81-9	15.4	31
110	Alternatively-spliced extra domain A of fibronectin promotes acute inflammation and brain injury after cerebral ischemia in mice. *Stroke*, **2012**, 43, 1376-82	6.7	54
109	ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. *Blood*, **2012**, 120, 5224-30	2.2	68
108	Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention During Surgical Procedures - Results From the guardian™ Trials.. *Blood*, **2012**, 120, 2228-2228	2.2	1

107	ADAMTS13 Deficiency Exacerbates VWF-Dependent Acute Myocardial Ischemia/Reperfusion Injury in Mice. *Blood*, **2012**, 120, 264-264	2.2	2
106	A Novel Approach to Capturing Post-Marketing Safety Information On Recombinant Factor VIIa (rFVIIa) in Acquired Hemophilia: Final Data From the Acquired Hemophilia Surveillance (AHS) Project. *Blood*, **2012**, 120, 3371-3371	2.2	
105	ADAMTS13 Reduces Vascular Inflammation and Early Development of Atherosclerosis Via VWF-Dependent Mechanism.. *Blood*, **2012**, 120, 2178-2178	2.2	
104	Durable responses to rituximab in acquired factor VIII deficiency. *Thrombosis and Haemostasis*, **2011**, 106, 172-4	7	10
103	Human thrombomodulin knock-in mice reveal differential effects of human thrombomodulin on thrombosis and atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 2509-17	9.4	7
102	The nutrigenetics of hyperhomocysteinemia: quantitative proteomics reveals differences in the methionine cycle enzymes of gene-induced versus diet-induced hyperhomocysteinemia. *Molecular and Cellular Proteomics*, **2010**, 9, 471-85	7.6	19
101	Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. *Circulation Research*, **2010**, 106, 551-8	15.7	31
100	Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. *Journal of Biological Chemistry*, **2010**, 285, 5385-91	5.4	84
99	Epigenetic regulation of hepatic endoplasmic reticulum stress pathways in the ethanol-fed cystathionine beta synthase-deficient mouse. *Hepatology*, **2010**, 51, 932-41	11.2	65
98	The Acquired Hemophilia Surveillance (AHS) Project: A Novel Mechanism of Capturing Post-Marketing Safety Information on rFVIIa (NovoSeven RT) In Acquired Hemophilia.. *Blood*, **2010**, 116, 3674-3674	2.2	
97	Durable Responses to Rituximab In Acquired Factor VIII Deficiency.. *Blood*, **2010**, 116, 3680-3680	2.2	
96	EDA-Containing Fibronectin Aggravates Ischemic Brain Injury In Mice. *Blood*, **2010**, 116, 330-330	2.2	
95	Countervailing effects on atherogenesis and plaque stability: a paradoxical benefit of hypercoagulability?. *Circulation*, **2009**, 120, 722-4	16.7	1
94	Role of hydrogen peroxide and the impact of glutathione peroxidase-1 in regulation of cerebral vascular tone. *Journal of Cerebral Blood Flow and Metabolism*, **2009**, 29, 1130-7	7.3	26
93	Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. *Blood*, **2009**, 114, 1666-74	2.2	81
92	Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. *Blood*, **2008**, 111, 1257-65	2.2	155
91	Glutathione peroxidase-1 plays a major role in protecting against angiotensin II-induced vascular dysfunction. *Hypertension*, **2008**, 51, 872-7	8.5	71
90	Murine models of hyperhomocysteinemia and their vascular phenotypes. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 1596-605	9.4	80

89	Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. *Stroke*, **2008**, 39, 180-4	6.7	67
88	Many Potential Explanations for the Homocysteine Paradox. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28,	9.4	1
87	Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 295, H816-25	5.2	47
86	The emerging role of asymmetric dimethylarginine in cardiovascular disease. *Arterial Hypertension (Russian Federation)*, **2008**, 14, 306-314	0.7	2
85	Role of redox reactions in the vascular phenotype of hyperhomocysteinemic animals. *Antioxidants and Redox Signaling*, **2007**, 9, 1899-909	8.4	19
84	Hypermethylation of Fads2 and altered hepatic fatty acid and phospholipid metabolism in mice with hyperhomocysteinemia. *Journal of Biological Chemistry*, **2007**, 282, 37082-90	5.4	63
83	Testosterone regulation of renal cystathionine beta-synthase: implications for sex-dependent differences in plasma homocysteine levels. *American Journal of Physiology - Renal Physiology*, **2007**, 293, F594-600	4.3	42
82	Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 175-81	9.4	65
81	Cerebral vascular dysfunction during hypercholesterolemia. *Stroke*, **2007**, 38, 2136-41	6.7	75
80	Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. *Journal of Neuroscience*, **2007**, 27, 2751-9	6.6	188
79	Prothrombotic effects of hyperhomocysteinemia and hypercholesterolemia in ApoE-deficient mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 233-40	9.4	38
78	Genetic Evidence that Cerebrovascular Responses to Arachidonic Acid are Mediated by Hydrogen Peroxide Produced by SOD-1. *FASEB Journal*, **2007**, 21, A1384	0.9	
77	A novel ELISA for mouse activated protein C in plasma. *Journal of Immunological Methods*, **2006**, 314, 174-81	2.5	16
76	Influence of folate on arterial permeability and stiffness in the absence or presence of hyperhomocysteinemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 814-8	9.4	24
75	ApoA-I: a missing link between homocysteine and lipid metabolism?. *Circulation Research*, **2006**, 98, 431-3	15.7	21
74	Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. *Blood*, **2006**, 108, 2237-43	2.2	78
73	Hyperhomocysteinemia increases arterial permeability and stiffness in mice. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2006**, 291, R1349-54	3.2	10
72	Overexpression of DDAH-1 in mice inhibits effects of ADMA on endothelial function in the cerebral circulation.. *FASEB Journal*, **2006**, 20, A731	0.9	

71	Cerebral vascular dysfunction in methionine synthase-deficient mice. *Circulation*, **2005**, 112, 737-44	16.7	54
70	Another lesson from the factor V Leiden mouse: thrombin generation drives arterial disease. *Circulation*, **2005**, 111, 1733-4	16.7	9
69	Role of FcRgamma and factor XIIIA in coated platelet formation. *Blood*, **2005**, 106, 4146-51	2.2	40
68	Mechanisms of homocysteine-induced atherothrombosis. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 1646-54	15.4	269
67	The benefits of excess EPCR. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 1349-50	15.4	2
66	ADMA and hyperhomocysteinemia. *Vascular Medicine*, **2005**, 10, S27-S33	3.3	48
65	Mechanisms of the atherogenic effects of elevated homocysteine in experimental models. *Seminars in Vascular Medicine*, **2005**, 5, 163-71		28
64	Tissue-specific changes in H19 methylation and expression in mice with hyperhomocysteinemia. *Journal of Biological Chemistry*, **2005**, 280, 25506-11	5.4	76
63	ADMA and hyperhomocysteinemia. *Vascular Medicine*, **2005**, 10 Suppl 1, S27-33	3.3	51
62	TNF Family Protein Regulation in Megakaryocytes and Platelets.. *Blood*, **2005**, 106, 4250-4250	2.2	
61	Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice. *Circulation*, **2004**, 110, 207-13	16.7	171
60	Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2004**, 287, R39-46	3.2	85
59	Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. *Cell Death and Differentiation*, **2004**, 11 Suppl 1, S56-64	12.7	280
58	Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. *Experimental Hematology*, **2004**, 32, 1073-81	3.1	31
57	Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. *Stroke*, **2004** , 35, 1957-62	6.7	135
56	Effect of Mthfr genotype on diet-induced hyperhomocysteinemia and vascular function in mice. *Blood*, **2004**, 103, 2624-9	2.2	89
55	Cerebral Vascular Dysfunction in Methionine Synthase-Deficient Mice.. *Blood*, **2004**, 104, 2617-2617	2.2	3
54	Homocysteine: is it a clinically important cardiovascular risk factor?. *Cleveland Clinic Journal of Medicine*, **2004**, 71, 729-34	2.8	72

53	Hyperhomocysteinemic Mice Have Increased Susceptibility to Carotid Artery Thrombosis.. *Blood*, **2004**, 104, 2616-2616	2.2	2
52	Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. *Blood*, **2003**, 102, 146-51	2.2	61
51	Effect of mechanical ventilation on carotid artery thrombosis induced by photochemical injury in mice. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 2669-74	15.4	25
50	Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. *Atherosclerosis Supplements*, **2003**, 4, 61-5	1.7	83
49	Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. *Immunity*, **2003**, 19, 9-19	32.3	296
48	Thrombosis of vein grafts: wall tension restrains thrombomodulin expression. *Circulation Research*, **2003**, 92, 12-3	15.7	88
47	Prothrombotic States that Predispose to Stroke. *Current Treatment Options in Neurology*, **2002**, 4, 417-425	1.4	15
46	Structure of cerebral arterioles in cystathionine beta-synthase-deficient mice. *Circulation Research*, **2002**, 91, 931-7	15.7	61
45	Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, 1996-2002	9.4	86
44	Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. *Circulation*, **2002**, 106, 842-6	16.7	17
43	Role of the adapter protein SLP-76 in GPVI-dependent platelet procoagulant responses to collagen. *Blood*, **2002**, 100, 2839-44	2.2	19
42	Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. *Blood*, **2002**, 99, 437-42	2.2	56
41	Effect of hyperhomocysteinemia on protein C activation and activity. *Blood*, **2002**, 100, 2108-12	2.2	31
40	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. *Clinical Science*, **2001**, 100, 161-167	6.5	143
39	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. *Clinical Science*, **2001**, 100, 161	6.5	66
38	Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. *Journal of Clinical Investigation*, **2001**, 107, 1263-73	15.9	538
37	Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. *Circulation Research*, **2001**, 88, 1203-9	15.7	179
36	Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys. *Circulation*, **2001**, 103, 1006-11	16.7	30

35	Does Homocysteine Promote Atherosclerosis?. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2001**, 21, 1385-1386	9.4	28
34	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. *Clinical Science*, **2001**, 100, 161-7	6.5	35
33	Folate dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine beta-synthase-deficient mice. *American Journal of Physiology - Heart and Circulatory Physiology*, **2000**, 279, H970-5	5.2	76
32	Electronic communication at arteriosclerosis, thrombosis, and vascular biology. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 1851	9.4	
31	Homocysteine and its disulfide derivatives: a suggested consensus terminology. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 1704-6	9.4	177
30	Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 1557-64	9.4	223
29	Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 1744-50	9.4	29
28	Expression of thrombomodulin and consequences of thrombomodulin deficiency during healing of cutaneous wounds. *American Journal of Pathology*, **1999**, 155, 1569-75	5.8	23
27	Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice. *Journal of Clinical Investigation* , **1999**, 103, 19-25	15.9	136
26	Remission after 13-cis retinoic acid in thrombotic thrombocytopenic purpura. *Lancet, The*, **1998**, 352, 454-5	40	17
25	Mechanisms of thrombosis in hyperhomocysteinemia. *Current Opinion in Hematology*, **1998**, 5, 343-9	3.3	50
24	Keratinocyte-specific expression of human thrombomodulin in transgenic mice: effects on epidermal differentiation and cutaneous wound healing. *Journal of Investigative Medicine*, **1998**, 46, 127-33	2.9	12
23	Homocysteine and vascular dysfunction. *Life Sciences*, **1997**, 61, 1205-15	6.8	104
22	Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 2930-4	9.4	58
21	Functional Interactions Between the Thrombin Receptor and the T-Cell Antigen Receptor in Human T-Cell Lines. *Blood*, **1997**, 90, 1893-1901	2.2	20
20	Atherosclerotic vascular disease: will folate or gene therapy be useful?. *Transactions of the American Clinical and Climatological Association*, **1997**, 108, 69-76; discussion 76-7	0.9	
19	Interference in protein C activation assays from endogenous serpins in mammalian host cells. *Thrombosis Research*, **1996**, 84, 373-7	8.2	
18	Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. *Journal of Clinical Investigation*, **1996**, 98, 24-9	15.9	380

17	Regulation of thrombomodulin expression by all-trans retinoic acid and tumor necrosis factor-alpha: differential responses in keratinocytes and endothelial cells. *Blood*, **1996**, 88, 2043-9	2.2	4
16	Cellular localization of thrombomodulin in human epithelium and squamous malignancies. *American Journal of Pathology*, **1995**, 146, 933-43	5.8	23
15	Thrombomodulin expression by human keratinocytes. Induction of cofactor activity during epidermal differentiation. *Journal of Clinical Investigation*, **1994**, 93, 1846-51	15.9	60
14	Structure-function relationships of the thrombin-thrombomodulin interaction. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **1993**, 23 Suppl 1, 183-93		16
13	Recurrent neuroendocrine (Merkel cell) carcinoma of the skin presenting as marrow failure in a man with systemic lupus erythematosus. *Medical and Pediatric Oncology*, **1993**, 21, 137-41		22
12	Sequences required for thrombomodulin cofactor activity within the fourth epidermal growth factor-like domain of human thrombomodulin. *Journal of Biological Chemistry*, **1993**, 268, 15312-7	5.4	17
11	Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. *Blood*, **1993**, 81, 683-9	2.2	15
10	Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. *Journal of Biological Chemistry*, **1992**, 267, 6164-70	5.4	64
9	Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 6775-9	11.5	122
8	Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. *Blood*, **1991**, 77, 542-50	2.2	30
7	Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. *Journal of Clinical Investigation*, **1991**, 88, 1906-14	15.9	335
6	Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy. *Cancer*, **1990**, 66, 1276-8	6.4	31
5	Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues. *Biochemistry*, **1990**, 29, 10602-12	3.2	86
4	Posttranslational modification of the carboxy-terminal region of the beta subunit of human chorionic gonadotropin. *Biochemistry*, **1984**, 23, 5330-7	3.2	9
3	Effects of 1,2-dimethoxyethane on the catalytic and coenzyme properties of glycogen phosphorylase. *Biochemistry*, **1981**, 20, 2537-44	3.2	17
2	Malate dehydrogenase: isolation from E. coli and comparison with the eukaryotic mitochondrial and cytoplasmic forms. *Bioscience Reports*, **1981**, 1, 497-507	4.1	26
1	Bleeding from Acquired Coagulation Defects and Antithrombotic Therapy376-390		3